July 2024 – Page 248 – Get News Story

Listeriosis Treatment Market 2034: FDA Approvals, Prevalence, Clinical Trials, Therapies, and Companies by DelveInsight

“Listeriosis Treatment Market”

Listeriosis companies are Emergent Bio Solutions Inc, Pfizer Inc, LimmaTech Biologics AG, GlaxoSmithKline plc, Zydus Cadila, Bionpharma, Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Fresenius Kabi AG, Novartis AG, WOCKHARDT, Mylan N.V., LUPIN, Sun Pharmaceutical Industries Ltd, Novel Laboratories Inc., Hainan Poly Co. Ltd, Amneal Pharmaceuticals LLC and others.

(Albany, USA) DelveInsight’s “Listeriosis Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Listeriosis, historical and forecasted epidemiology as well as the Listeriosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Listeriosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Listeriosis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Listeriosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Listeriosis market.

Request for a Free Sample Report @ Listeriosis Market Forecast

Some facts of the Listeriosis market report are:

According to DelveInsight, Listeriosis market size is expected to grow at a decent CAGR by 2034.
Leading Listeriosis companies working in the market are Emergent Bio Solutions Inc, Pfizer Inc, LimmaTech Biologics AG, GlaxoSmithKline plc, Zydus Cadila, Bionpharma, Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Fresenius Kabi AG, Novartis AG, WOCKHARDT, Mylan N.V., LUPIN, Sun Pharmaceutical Industries Ltd, Novel Laboratories Inc., Hainan Poly Co. Ltd, Amneal Pharmaceuticals LLC and others.
The increase in the number of people suffering from listeriosis infection treatment market across the globe acts as one of the major factors driving the growth of listeriosis infection treatment market.
Although, lack of novel disease specific treatment and low healthcare budget in some developing countries are expected to obstruct the market growth.
The MONALISA-GENBIO study is a national case-control prospective study on listeriosis. It aims to identify human genetic susceptibility factors to listeriosis and evaluate biomarkers for diagnosis and prognosis. The study collects clinical and biological data from patients with listeriosis and includes controls with comparable backgrounds.
On August 11, 2023, in conjunction with regional and local partners, Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) are looking into a listeria monocytogenes infection outbreak that may be related to Real Kosher Ice Cream of Brooklyn, New York’s Soft Serve On The Go ice cream cups.
On May 12, 2022, following the treatment of Listeria monocytogenes-infected cells with ampicillin, researchers noticed intracellular production of antibiotic-resistant Listeria monocytogenes L-forms. The findings reported here give compelling evidence that antibiotic administration to infected host cells can cause intracellular Listeria monocytogenes to produce L-forms. Furthermore, these findings imply that intracellular L-forms remain inside host cells indicating that they represent live, still-growing, proliferating bacteria.

Listeriosis Overview

Listeriosis is a bacterial infection caused by the bacterium Listeria monocytogenes. While it primarily affects pregnant women, newborns, elderly individuals, and those with weakened immune systems, it can also impact healthy individuals. The bacterium is commonly found in soil, water, and some animal products, including unpasteurized dairy products and raw meats.

Symptoms of listeriosis can vary but often include fever, muscle aches, nausea, diarrhea, and gastrointestinal symptoms. In severe cases, the infection can lead to meningitis, septicemia, or miscarriage in pregnant women.

Diagnosis typically involves blood or cerebrospinal fluid cultures to identify the presence of Listeria monocytogenes. Treatment usually consists of antibiotics, such as ampicillin or penicillin, although antibiotic resistance can complicate therapy.

Prevention strategies include practicing good food safety habits, such as thoroughly cooking meat and washing fruits and vegetables, as well as avoiding unpasteurized dairy products and deli meats unless heated to a safe temperature. Pregnant women and individuals with weakened immune systems should take extra precautions to minimize their risk of exposure.

Prompt medical attention is crucial for individuals suspected of having listeriosis, particularly those at higher risk of severe complications. Public health efforts also focus on surveillance, outbreak investigation, and education to prevent and control listeriosis infections.

Learn more about Listeriosis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Listeriosis Treatment Market

Listeriosis Market

The Listeriosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Listeriosis market trends by analyzing the impact of current Listeriosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Listeriosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Listeriosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Listeriosis market in 7MM is expected to witness a major change in the study period 2020-2034.

Listeriosis Epidemiology

The Listeriosis epidemiology section provides insights into the historical and current Listeriosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Listeriosis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Listeriosis Epidemiology @ Listeriosis Prevalence

Listeriosis Drugs Uptake

This section focuses on the uptake rate of the potential Listeriosis drugs recently launched in the Listeriosis market or expected to be launched in 2020-2034. The analysis covers the Listeriosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Listeriosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Listeriosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Listeriosis Pipeline Development Activities

The Listeriosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Listeriosis key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Listeriosis pipeline development activities @ Listeriosis Drugs Market

Listeriosis Therapeutics Assessment

Major key companies are working proactively in the Listeriosis Therapeutics market to develop novel therapies which will drive the Listeriosis treatment markets in the upcoming years are Emergent Bio Solutions Inc, Pfizer Inc, LimmaTech Biologics AG, GlaxoSmithKline plc, Zydus Cadila, Bionpharma, Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Fresenius Kabi AG, Novartis AG, WOCKHARDT, Mylan N.V., LUPIN, Sun Pharmaceutical Industries Ltd, Novel Laboratories Inc., Hainan Poly Co. Ltd, Amneal Pharmaceuticals LLC and others.

Learn more about the emerging Listeriosis therapies & key companies @ Listeriosis Clinical Trials and FDA Approvals

Listeriosis Report Key Insights

1. Listeriosis Patient Population

2. Listeriosis Market Size and Trends

3. Key Cross Competition in the Listeriosis Market

4. Listeriosis Market Dynamics (Key Drivers and Barriers)

5. Listeriosis Market Opportunities

6. Listeriosis Therapeutic Approaches

7. Listeriosis Pipeline Analysis

8. Listeriosis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Listeriosis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Listeriosis Competitive Intelligence Analysis

4. Listeriosis Market Overview at a Glance

5. Listeriosis Disease Background and Overview

6. Listeriosis Patient Journey

7. Listeriosis Epidemiology and Patient Population

8. Listeriosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Listeriosis Unmet Needs

10. Key Endpoints of Listeriosis Treatment

11. Listeriosis Marketed Products

12. Listeriosis Emerging Therapies

13. Listeriosis Seven Major Market Analysis

14. Attribute Analysis

15. Listeriosis Market Outlook (7 major markets)

16. Listeriosis Access and Reimbursement Overview

17. KOL Views on the Listeriosis Market

18. Listeriosis Market Drivers

19. Listeriosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Listeriosis Treatment Market 2034: FDA Approvals, Prevalence, Clinical Trials, Therapies, and Companies by DelveInsight

Oligometastatic Disease Treatment Market 2034: FDA Approvals, Prevalence, Clinical Trials, Therapies, and Companies by DelveInsight

“Oligometastatic Disease Treatment Market”

Oligometastatic Disease companies are Merck, Philogen, AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, CELGENE, Lilly, Roche, Johnson & Johnson, Pfizer, Sanofi, Takeda, GlaxoSmithKline, Amgen, Akorn, Reata Pharmaceuticals, Genentech, and others.

(Albany, USA) DelveInsight’s “Oligometastatic Disease Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Oligometastatic Disease, historical and forecasted epidemiology as well as the Oligometastatic Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Oligometastatic Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Oligometastatic Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Oligometastatic Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Oligometastatic Disease market.

Request for a Free Sample Report @ Oligometastatic Disease Market Forecast

Some facts of the Oligometastatic Disease Market Report are:

According to DelveInsight, Oligometastatic Disease market size is expected to grow at a decent CAGR by 2034.
In 2022, the oligometastatic disease market size in the United States was approximately USD 960 million, which is expected to grow further by 2034.
Leading Oligometastatic Disease companies working in the market are Merck & Co., Inc., Philogen, AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Lilly, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Pfizer Inc., Sanofi, Takeda Pharma, ImmuneSensor Therapeutics, POINT Biopharma GlaxoSmithKline plc., Promega Corporation, Amgen Inc., Akorn, Reata Pharmaceuticals, Inc. and Genentech, among others.
Key Oligometastatic Disease Therapies expected to launch in the market are IMSA101, PNT2002, Gadoxetate disodium and others.
On Feb 2024, ImmuneSensor Therapeutics Inc announced results of a Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered With or Without STING-Agonist IMSA101 in Patients With Oligometastatic NSCLC and RCC.

Oligometastatic Disease Overview

Oligometastatic disease refers to a state in which cancer has spread beyond its primary site but is limited to a small number of metastases, typically fewer than five lesions in a limited number of organs. This condition represents an intermediate state between localized and widely metastatic cancer. Oligometastases are believed to arise due to the tumor’s ability to spread before becoming widespread.

The concept of oligometastatic disease has gained significant interest in oncology because patients with oligometastases may have a better prognosis and potentially benefit from more aggressive treatment strategies such as surgical resection, radiotherapy, or ablative techniques. These interventions aim to eradicate or control the limited metastatic lesions, potentially delaying disease progression and improving survival outcomes. However, patient selection and careful consideration of treatment risks and benefits are crucial in managing oligometastatic disease effectively. Ongoing research aims to better understand the biology of oligometastases and optimize treatment approaches.

Learn more about Oligometastatic Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Oligometastatic Disease Treatment Market

Oligometastatic Disease Market

The Oligometastatic Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Oligometastatic Disease market trends by analyzing the impact of current Oligometastatic Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Oligometastatic Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Oligometastatic Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Oligometastatic Disease market in 7MM is expected to witness a major change in the study period 2020-2034.

Oligometastatic Disease Epidemiology

The Oligometastatic Disease epidemiology section provides insights into the historical and current Oligometastatic Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Oligometastatic Disease market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Oligometastatic Disease Epidemiology @ Oligometastatic Disease Prevalence

Oligometastatic Disease Drugs Uptake

This section focuses on the uptake rate of the potential Oligometastatic Disease drugs recently launched in the Oligometastatic Disease market or expected to be launched in 2020-2034. The analysis covers the Oligometastatic Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Oligometastatic Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Oligometastatic Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Oligometastatic Disease Pipeline Development Activities

The Oligometastatic Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Oligometastatic Disease key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Oligometastatic Disease pipeline development activities @ Oligometastatic Disease Therapies and Drugs

Oligometastatic Disease Therapeutics Assessment

Major key companies are working proactively in the Oligometastatic Disease Therapeutics market to develop novel therapies which will drive the Oligometastatic Disease treatment markets in the upcoming years are Merck & Co., Inc., Philogen, AbbVie Inc., Amgen Inc., AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Lilly, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc., Pfizer Inc., Sanofi, Takeda Pharma, ImmuneSensor Therapeutics, POINT Biopharma GlaxoSmithKline plc., Promega Corporation, Amgen Inc., Akorn, Reata Pharmaceuticals, Inc. and Genentech, among others.

Learn more about the emerging Oligometastatic Disease therapies & key companies @ Oligometastatic Disease FDA Approvals and Clinical Trials

Oligometastatic Disease Report Key Insights

1. Oligometastatic Disease Patient Population

2. Oligometastatic Disease Market Size and Trends

3. Key Cross Competition in the Oligometastatic Disease Market

4. Oligometastatic Disease Market Dynamics (Key Drivers and Barriers)

5. Oligometastatic Disease Market Opportunities

6. Oligometastatic Disease Therapeutic Approaches

7. Oligometastatic Disease Pipeline Analysis

8. Oligometastatic Disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Oligometastatic Disease Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Oligometastatic Disease Competitive Intelligence Analysis

4. Oligometastatic Disease Market Overview at a Glance

5. Oligometastatic Disease Disease Background and Overview

6. Oligometastatic Disease Patient Journey

7. Oligometastatic Disease Epidemiology and Patient Population

8. Oligometastatic Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Oligometastatic Disease Unmet Needs

10. Key Endpoints of Oligometastatic Disease Treatment

11. Oligometastatic Disease Marketed Products

12. Oligometastatic Disease Emerging Therapies

13. Oligometastatic Disease Seven Major Market Analysis

14. Attribute Analysis

15. Oligometastatic Disease Market Outlook (7 major markets)

16. Oligometastatic Disease Access and Reimbursement Overview

17. KOL Views on the Oligometastatic Disease Market

18. Oligometastatic Disease Market Drivers

19. Oligometastatic Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Oligometastatic Disease Treatment Market 2034: FDA Approvals, Prevalence, Clinical Trials, Therapies, and Companies by DelveInsight

Top Real Estate Agent in Menlo Park, CA, Marks 4th Year in Business

This year marks the fourth anniversary of the Dana Carmel Group, a standout real estate agency led by Dana Carmel, a top real estate agent in Menlo Park, CA. Celebrating a milestone in Silicon Valley, Dana and her team are recognized for their unparalleled dedication to clients in one of the nation’s most competitive markets.

Reflecting on her team’s achievements, Dana, a renowned Realtor in Menlo Park, CA, says, “These four years have been incredibly rewarding. We’ve not only grown our presence but have significantly impacted the lives of our clients through dedicated service and deep market insight.” Dana’s group is celebrated for surpassing $200 million in sales, positioning her among the Top 1% of Realtors nationwide according to Real Trends.

Dana’s firm is a key player in the San Mateo County Top Agent Network, granting clients exclusive access to sought-after off-market listings. This insider advantage is crucial for success in Silicon Valley’s dynamic housing landscape and represents a significant benefit Dana’s team offers over competitors.

The team’s approach goes beyond traditional buying and selling. They provide comprehensive support tailored to each client’s needs, ensuring smooth transactions and maximum satisfaction. “Our objective is to streamline the complex process of real estate transactions, making it as seamless as possible for our clients while securing the best outcomes,” Dana elaborates.

As a Realtor agent in Menlo Park, CA, Dana emphasizes the importance of a hands-on approach and a commitment to client relationships, which have been pivotal to her team’s success. Their deep local knowledge and extensive network have enabled them to handle a wide range of real estate needs, from buying and selling to detailed market analysis and property customization.

To discover more about the Dana Carmel Group or to start your real estate journey in Menlo Park, visit Dana Carmel Group’s website. Engage with Dana, a leading real estate selling agent in Menlo Park, CA, and experience the exceptional service and results that her team is known to provide.

Media Contact
Company Name: Dana Carmel Group | Top Realtor I Menlo Park I Atherton
Contact Person: Dana Carmel
Email: Send Email
Phone: +1 650-804-2393
Address:1300 El Camino Real
City: Menlo Park
State: California 94025
Country: United States
Website: https://www.danacarmelgroup.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Agent in Menlo Park, CA, Marks 4th Year in Business

Top Real Estate Selling Agent in Lafayette, CA, Sets New Standard with Quick Sale Above Asking Price

Lafayette, CA – Omar Khan, a top real estate selling agent in Lafayette, CA, has set a new benchmark by getting a home into contract significantly above the asking price in just five days. This achievement highlights Omar’s proficiency in the competitive Lafayette real estate market.

The sold property on Silver Springs Road in Lafayette, CA, features 4 bedrooms, 3 bathrooms and 1,891 square feet of living space on a .48-acre lot. Initially listed at $1,995,000, it sold for an astonishing $2,475,000, $480,000 over the list price, after receiving multiple offers. Omar Khan’s strategic planning and collaboration with his colleague played a crucial role in this swift and successful sale.

Omar’s role extended beyond mere representation as a Lafayette, CA Realtor; he was instrumental in the project management of the listing refresh and improvement. His efforts included an estate sale, new roof installation, and other enhancements that showcased the property’s best features. “From the initial stages of preparing the home, including an estate sale and new roof installation, to securing a buyer contract in just five days, this project was incredibly rewarding for our team,” stated Omar Khan.

This accomplishment underscores Omar’s reputation as a leading real estate listing agent in Lafayette, CA. His dedication to providing exceptional service and his comprehensive understanding of the market ensure that clients receive the best possible outcomes. The picturesque setting of the property in the Silver Springs enclave added to its appeal, making it a sought-after home.

For those interested in working with a top Realtor agent in Lafayette, CA, Omar Khan is the professional to contact. His track record of successful sales and client satisfaction speaks volumes about his capabilities. Visit https://kellycrawfordhomes.com/agents/omar-khan to learn more about his services and to get started on your real estate journey.

Contact Omar Khan today to experience exceptional service and expertise in the Lafayette real estate market. Benefit from his proven track record of successful sales and client satisfaction.

Media Contact
Company Name: Omar Khan, Realtor® | Real Estate Agent in Lafayette, CA
Contact Person: Omar Khan
Email: Send Email
Phone: +1 925-705-1609
Address:971 Dewing Ave
City: Lafayette
State: California 94549
Country: United States
Website: https://kellycrawfordhomes.com/agents/omar-khan

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Real Estate Selling Agent in Lafayette, CA, Sets New Standard with Quick Sale Above Asking Price

Acromegaly Drugs Market 2032: FDA Approvals, Prevalence, Clinical Trials, Therapies, and Companies by DelveInsight | Paltusotine (CRN 00808), CAM-2029 (octreotide subcutaneous depot), more

“Acromegaly Drugs Market”

Acromegaly companies are Amolyt Pharma, Amryt Pharma, Antisense Therapeutics, Aquestive Therapeutics, ASCIL Biopharm, Camurus AB, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Debiopharm International, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, GeneScience Pharmaceuticals, Genevant Sciences Ltd, GlyTech Inc, Ionis Pharmaceuticals Inc, Italfarmaco SpA, OPKO Health Inc, Pharmathen Global BV, Rani Therapeutics, Strongbridge Biopharma plc., and others.

(Albany, USA) DelveInsight’s “Acromegaly Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Acromegaly, historical and forecasted epidemiology as well as the Acromegaly market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Acromegaly market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Acromegaly market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Acromegaly treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Acromegaly market.

Request for a Free Sample Report @ Acromegaly Market Forecast

Some facts of the Acromegaly Market Report are:

According to DelveInsight, Acromegaly market size is expected to grow at a decent CAGR by 2032.
In 2022, the United States had the largest Acromegaly market size of ~USD 700 million among the 7MM countries.
Leading Acromegaly companies working in the market are Amolyt Pharma, Amryt Pharma Plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, ASCIL Biopharm, Camurus AB, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Debiopharm International SA, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, GeneScience Pharmaceuticals Co Ltd, Genevant Sciences Ltd, GlyTech Inc, Ionis Pharmaceuticals Inc, Italfarmaco SpA, OPKO Health Inc, Pharmathen Global BV, Rani Therapeutics LLC, Strongbridge Biopharma plc., and others.
Key Acromegaly Therapies expected to launch in the market are Paltusotine (CRN 00808), CAM-2029 (octreotide subcutaneous depot), and many others.
On March 2024, Crinetics Pharmaceuticals announced results of a Randomized, Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects With Non-pharmacologically Treated Acromegaly (PATHFNDR-2)
On April 2024, Camurus AB announced results of a Phase 3, Open-label, Single-arm, Multi-center Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
On September 2023, Pfizer announced results of a non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

Acromegaly Overview

Acromegaly is a rare hormonal disorder caused by excessive production of growth hormone (GH) in adulthood, usually due to a benign tumor in the pituitary gland. This surplus of GH leads to abnormal growth of bones and tissues, resulting in characteristic symptoms such as enlarged hands, feet, and facial features. Other Acromegaly signs include joint pain, thickened skin, and enlarged organs like the heart. If left untreated, acromegaly can lead to serious complications including cardiovascular disease, diabetes, and arthritis. Acromegaly Diagnosis typically involves blood tests to measure GH levels and imaging scans to locate any tumors. Acromegaly Treatment aims to reduce GH production, either through surgery to remove the tumor, medications to suppress hormone release, or radiation therapy in some cases. Regular monitoring is essential to manage symptoms and prevent complications. Early detection and intervention can significantly improve outcomes and quality of life for individuals with acromegaly.

Do you know what will be the Acromegaly market share in 7MM by 2032 @ Acromegaly Treatment Market

Acromegaly Market

The Acromegaly market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Acromegaly market trends by analyzing the impact of current Acromegaly therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Acromegaly market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Acromegaly market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Acromegaly market in 7MM is expected to witness a major change in the study period 2019-2032.

Acromegaly Epidemiology

The Acromegaly epidemiology section provides insights into the historical and current Acromegaly patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acromegaly market report also provides the diagnosed patient pool, trends, and assumptions.

Interested to know how the emerging diagnostic approaches will be contributing in increased Acromegaly diagnosed prevalence pool? Download report @ Acromegaly Prevalence

Acromegaly Drugs Uptake

This section focuses on the uptake rate of the potential Acromegaly drugs recently launched in the Acromegaly market or expected to be launched in 2019-2032. The analysis covers the Acromegaly market uptake by drugs, patient uptake by therapies, and sales of each drug.

Acromegaly Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acromegaly market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acromegaly Pipeline Development Activities

The Acromegaly report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acromegaly key players involved in developing targeted therapeutics.

Download report to know which TOP 3 therapies will be capturing the largest Acromegaly market share by 2032? Click here @ Acromegaly Therapeutics Market

Acromegaly Therapeutics Assessment

Major key companies are working proactively in the Acromegaly Therapeutics market to develop novel therapies which will drive the Acromegaly treatment markets in the upcoming years are Amolyt Pharma, Amryt Pharma Plc, Antisense Therapeutics Ltd, Aquestive Therapeutics Inc, ASCIL Biopharm, Camurus AB, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Debiopharm International SA, DexTech Medical AB, Enesi Pharma Ltd, Foresee Pharmaceuticals Co Ltd, GeneScience Pharmaceuticals Co Ltd, Genevant Sciences Ltd, GlyTech Inc, Ionis Pharmaceuticals Inc, Italfarmaco SpA, OPKO Health Inc, Pharmathen Global BV, Rani Therapeutics LLC, Strongbridge Biopharma plc., and others.

Do you know how Paltusotine (CRN 00808) and CAM-2029 market launch will be impacting the Acromegaly market CAGR? Download sample report @ Acromegaly Drugs Market

Acromegaly Report Key Insights

1. Acromegaly Patient Population

2. Acromegaly Market Size and Trends

3. Key Cross Competition in the Acromegaly Market

4. Acromegaly Market Dynamics (Key Drivers and Barriers)

5. Acromegaly Market Opportunities

6. Acromegaly Therapeutic Approaches

7. Acromegaly Pipeline Analysis

8. Acromegaly Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Acromegaly Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Acromegaly Competitive Intelligence Analysis

4. Acromegaly Market Overview at a Glance

5. Acromegaly Disease Background and Overview

6. Acromegaly Patient Journey

7. Acromegaly Epidemiology and Patient Population

8. Acromegaly Treatment Algorithm, Current Treatment, and Medical Practices

9. Acromegaly Unmet Needs

10. Key Endpoints of Acromegaly Treatment

11. Acromegaly Marketed Products

12. Acromegaly Emerging Therapies

13. Acromegaly Seven Major Market Analysis

14. Attribute Analysis

15. Acromegaly Market Outlook (7 major markets)

16. Acromegaly Access and Reimbursement Overview

17. KOL Views on the Acromegaly Market

18. Acromegaly Market Drivers

19. Acromegaly Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Acromegaly Drugs Market 2032: FDA Approvals, Prevalence, Clinical Trials, Therapies, and Companies by DelveInsight | Paltusotine (CRN 00808), CAM-2029 (octreotide subcutaneous depot), more

Actinic Keratosis Drugs Market 2032: FDA Approvals, Clinical Trials, Pipeline, Prevalence and Companies by DelveInsight

“Actinic Keratosis Drugs Market”

Actinic Keratosis companies are VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, Sol-Gel Technologies, Coegin Pharma, Jupiter Wellness, MedC Biopharma CorporationGlaukos Corporation, Ivantis Inc., Allergan, Ellex, Alcon, BVI, Johnson and Johnson Services, Inc., Microsurgical technology, Molteno Ophthalmic Ltd. ,New World Medical , Santen Pharmaceutical, Sight Scientific, Topcon Corporation, Merck, Alimera Sciences, Annexin Pharmaceuticals, Amgen, more

DelveInsight’s “Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Actinic Keratosis, historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Actinic Keratosis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Actinic Keratosis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Actinic Keratosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Actinic Keratosis market.

Request for a Free Sample Report @ Actinic Keratosis Market Forecast

Some facts of the Actinic Keratosis Market Report are:

According to DelveInsight, Actinic Keratosis market size is expected to grow at a decent CAGR by 2032.
Leading Actinic Keratosis companies working in the market are VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma CorporationGlaukos Corporation, Ivantis Inc., Allergan, Ellex, Alcon, BVI, Johnson and Johnson Services, Inc., Microsurgical technology, Molteno Ophthalmic Ltd. ,New World Medical , Santen Pharmaceutical, Sight Scientific, Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, Alimera Sciences, Annexin Pharmaceuticals, Amgen Inc., Cangene Corporation, BD and Bosch Healthcare Solutions GmbH among others.
Key Actinic Keratosis Therapies expected to launch in the market are AVX001, VDA-1102, and others.

Actinic Keratosis Overview

Actinic keratosis (AK) is a common skin condition characterized by rough, scaly patches that develop due to long-term exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Actinic keratosis usually occurs on areas of the body that receive the most sun exposure, such as the face, scalp, ears, neck, and hands.

These lesions are usually small, red, or flesh-colored, with a rough texture resembling sandpaper. While actinic keratosis is not cancerous in itself, it is considered a precancerous condition, as a small percentage of Actinic keratosis may progress to squamous cell carcinoma, a type of skin cancer.

It is important to have Actinic keratosis evaluated and treated by a healthcare professional. Treatment options include topical creams, cryotherapy (freezing), chemical peels, photodynamic therapy, or surgical removal. Prevention is crucial, and measures such as sun protection (using sunscreen, wearing protective clothing, and seeking shade), regular skin examinations, and avoiding artificial UV radiation can help reduce the risk of developing actinic keratosis. Early detection and treatment of Actinic keratosis can significantly lower the risk of skin cancer.

Learn more about Actinic Keratosis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Actinic Keratosis Treatment Market

Actinic Keratosis Market

The Actinic Keratosis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Actinic Keratosis market trends by analyzing the impact of current Actinic Keratosis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Actinic Keratosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Actinic Keratosis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Actinic Keratosis market in 7MM is expected to witness a major change in the study period 2019-2032.

Actinic Keratosis Epidemiology

The Actinic Keratosis epidemiology section provides insights into the historical and current Actinic Keratosis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Actinic Keratosis market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Actinic Keratosis Epidemiology @ Actinic Keratosis Prevalence

Actinic Keratosis Drugs Uptake

This section focuses on the uptake rate of the potential Actinic Keratosis drugs recently launched in the Actinic Keratosis market or expected to be launched in 2019-2032. The analysis covers the Actinic Keratosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Actinic Keratosis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Actinic Keratosis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Actinic Keratosis Pipeline Development Activities

The Actinic Keratosis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Actinic Keratosis key players involved in developing targeted therapeutics.

Learn more about the emerging Actinic Keratosis Market drivers and barriers @ Actinic Keratosis Market Dynamics

Actinic Keratosis Therapeutics Assessment

Major key companies are working proactively in the Actinic Keratosis Therapeutics market to develop novel therapies which will drive the Actinic Keratosis treatment markets in the upcoming years are VidacPharma, DFB Soria, G&E Herbal Biotechnology, Promius Pharma, Sol-Gel Technologies, PROVECTUS BIOPHARMACEUTICALS, Coegin Pharma, Jupiter Wellness, MedC Biopharma CorporationGlaukos Corporation, Ivantis Inc., Allergan, Ellex, Alcon, BVI, Johnson and Johnson Services, Inc., Microsurgical technology, Molteno Ophthalmic Ltd. ,New World Medical , Santen Pharmaceutical, Sight Scientific, Topcon Corporation, Merck & Co., Inc., Carl Zeiss AG, Alimera Sciences, Annexin Pharmaceuticals, Amgen Inc., Cangene Corporation, BD and Bosch Healthcare Solutions GmbH among others.

Learn more about the emerging Actinic Keratosis therapies & key companies @ Actinic Keratosis Therapies and Companies

Actinic Keratosis Report Key Insights

1. Actinic Keratosis Patient Population

2. Actinic Keratosis Market Size and Trends

3. Key Cross Competition in the Actinic Keratosis Market

4. Actinic Keratosis Market Dynamics (Key Drivers and Barriers)

5. Actinic Keratosis Market Opportunities

6. Actinic Keratosis Therapeutic Approaches

7. Actinic Keratosis Pipeline Analysis

8. Actinic Keratosis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Actinic Keratosis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Actinic Keratosis Competitive Intelligence Analysis

4. Actinic Keratosis Market Overview at a Glance

5. Actinic Keratosis Disease Background and Overview

6. Actinic Keratosis Patient Journey

7. Actinic Keratosis Epidemiology and Patient Population

8. Actinic Keratosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Actinic Keratosis Unmet Needs

10. Key Endpoints of Actinic Keratosis Treatment

11. Actinic Keratosis Marketed Products

12. Actinic Keratosis Emerging Therapies

13. Actinic Keratosis Seven Major Market Analysis

14. Attribute Analysis

15. Actinic Keratosis Market Outlook (7 major markets)

16. Actinic Keratosis Access and Reimbursement Overview

17. KOL Views on the Actinic Keratosis Market

18. Actinic Keratosis Market Drivers

19. Actinic Keratosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Actinic Keratosis Drugs Market 2032: FDA Approvals, Clinical Trials, Pipeline, Prevalence and Companies by DelveInsight

The Short Term Shop: Revolutionizing the Vacation Rental Market with Expertise and Innovation

The Short Term Shop specializes in short-term rental real estate, helping investors buy, sell, and manage properties.

The Short Term Shop, a trailblazer in the vacation rental industry, is proud to announce significant milestones and strategic expansions that continue positioning the company as a leader in short term rental investing. With over 5,000 vacation properties sold and recognition as the #1 team worldwide at EXP from 2022 to 2024, The Short Term Shop offers unparalleled expertise in over 20 top vacation markets across the United States.

Founded by Avery Carl, The Short Term Shop empowers new and seasoned investors to navigate the profitable avenues of short term rental investment. The company’s strategic presence in key locations like the Great Smoky Mountains, the Emerald Coast, and Orlando, among many others, ensures clients have access to prime vacation rental markets. Their comprehensive service suite includes buying, selling, learning opportunities, and property management, backed by a robust team of over 75 local experts.

The Short Term Shop offers local expertise with dedicated agents in over 20 vacation markets. They provide comprehensive education and support to help investors maximize their returns and a client-centric approach that tailors services to meet diverse investor needs. The company also leverages cutting-edge technology to streamline the investment process, making it easier for clients to find and manage their properties efficiently. Their innovative approach includes detailed market analysis, personalized investment strategies, and hands-on support from acquisition to management.

The Short Term Shop’s commitment to excellence has garnered it a loyal client base and numerous accolades within the real estate industry. As the vacation rental market continues to grow, The Short Term Shop remains at the forefront, continuously adapting and innovating to meet its clients’ evolving needs. Its proactive approach ensures that investors achieve and exceed their financial goals.

About The Short Term Shop

The Short Term Shop specializes in short term rental realtor services, focusing on maximizing investor returns through expert market insights and personalized service. The company is a cornerstone of success in the vacation rental market.

Media Contact
Company Name: The Short Term Shop
Email: Send Email
Phone: (865) 868-3233
Country: United States
Website: https://theshorttermshop.com/

Spring Hill Family Paving Explains Key Considerations for Choosing a Qualified Asphalt Paving Contractor

Spring Hill Family Paving is a leading asphalt paving company. In a recent update, the company explained key considerations for choosing a qualified asphalt paving contractor.

Spring Hill, TN – In a website post, Spring Hill Family Paving explained key considerations for choosing a qualified asphalt paving contractor.

The professionals noted that contractors holding valid state licenses demonstrate adherence to established regulations and possess the necessary qualifications. This verification safeguards against potential legal or safety concerns. Asphalt paving Spring Hill contractors carry liability and worker’s compensation insurance, protecting both the contractor’s team and the property owner in the event of unforeseen circumstances that may arise during construction.

The team asserted that a track record of successful projects completed by experienced professionals inspires confidence. Seeking out contractors with a demonstrably positive reputation and a history of satisfied clientele is a wise strategy. Verifying online reviews and requesting references from past clients allows for a more informed decision. Ideally, the asphalt contractor Spring Hill should possess specific experience with projects similar in scope and scale to the one envisioned.

The paving contractor Spring Hill said that before any work commences, a detailed written contract outlining the project’s specifics is essential. This document should meticulously detail the exact work to be performed, the materials to be utilized, a clearly defined timeline for project completion, and a comprehensive breakdown of all associated costs. Obtaining multiple proposals and comparing them carefully is highly recommended.

About Spring Hill Family Paving

Spring Hill Family Paving is a top-rated asphalt paving company. They utilize only the highest-quality materials and industry best practices to deliver long-lasting, durable asphalt surfaces. The crew prioritizes open communication and transparent pricing, providing clients with free estimates and upfront costs. The company takes pride in building trust with its customers and does everything possible to ensure a positive experience throughout the project.

Media Contact
Company Name: Spring Hill Family Paving
Contact Person: Fred Edwards
Email: Send Email
Phone: (931) 740-1011
Address:Parkfield Loop N
City: Spring Hill
State: TN
Country: United States
Website: https://springhillfamilypaving.com/

Anytime Restoration Fire Water Damage Highlights Environmental Considerations in Water Damage Restoration Eden Prairie

Anytime Restoration Fire Water Damage Eden Prairie is a leading water damage restoration company. The company recently highlighted environmental considerations in water damage restoration in a recent update.

Eden Prairie, MN – In a website post, Anytime Restoration Fire Water Damage Eden Prairie highlighted environmental considerations in water damage restoration.

The technicians said that proper waste disposal is vital to water damage restoration Eden Prairie. Materials such as soaked carpets, damaged drywall, and contaminated insulation must be disposed of responsibly. Improper disposal can cause environmental contamination and potential health hazards. Making sure that all waste is handled in accordance with local regulations and guidelines can significantly reduce the negative impact on the environment.

The experts mentioned that preventing mold growth is another essential environmental consideration in water damage restoration in Eden Prairie. Mold can develop rapidly in damp conditions, and its spores can spread through the air, affecting indoor air quality and leading to respiratory problems. Restoration efforts should prioritize thorough drying and dehumidification of affected areas to prevent mold proliferation.

Lastly, the professionals asserted that using eco-friendly cleaning products during the water restoration Eden Prairie process helps protect human health and the environment. Many traditional cleaning agents contain harsh chemicals that can be toxic when in the environment. By opting for biodegradable and non-toxic alternatives, the restoration process can effectively clean and sanitize without leaving behind harmful residues. These green products are just as effective in tackling the aftermath of water damage while ensuring a safer, more sustainable approach to restoration.

About Anytime Restoration Fire Water Damage Eden Prairie

Anytime Restoration Fire Water Damage Eden Prairie is a premier water damage restoration company. Dedicated to excellence, the business employs highly trained professionals with the latest technology and techniques. This ensures a thorough and efficient response to any water damage scenario, minimizing damage and reducing recovery time. Their knowledge covers residential, commercial, and industrial properties, offering comprehensive services that include assessment, mitigation, and complete restoration.

Anytime Restoration Fire Water Damage Eden Prairie

6640 Shady Oak Rd Suite #35, Eden Prairie, MN 55344

(952) 395-3815

Media Contact
Company Name: Anytime Restoration Fire Water Damage Eden Prairie
Contact Person: Curt Olejnicak
Email: Send Email
Phone: 612-249-0222
City: Eden Prairie
State: Minnesota
Country: United States
Website: https://www.anytimerestoration.com/eden-prairie-mn-water-fire-and-mold-damage-restoration/

Ez Car Keyz Oxnard Unveils Sleek New Website Design, Elevating Car Locksmith Services in Oxnard, CA

Oxnard, CA – July 03, 2024 – Ez Car Keyz Oxnard, a leading provider of car locksmith services in Oxnard, CA, is proud to announce the launch of its newly redesigned website. The revamped online platform showcases a modern and user-friendly interface, offering enhanced accessibility and functionality for customers seeking automotive locksmith solutions.

The redesigned website features a streamlined layout and intuitive navigation, allowing users to effortlessly explore Ez Car Keyz Oxnard’s comprehensive range of services, including car key replacement, lockout assistance, ignition repair, and key fob programming. With an emphasis on user experience, the website is optimized for desktop and mobile devices, ensuring seamless access to vital information and services on the go.

“We’re excited to introduce our fresh new website design, which reflects our commitment to delivering exceptional locksmith services with a modern touch,” said Niv Levy, Owner of Ez Car Keyz Oxnard. “Our goal is to provide our customers in Oxnard and the surrounding areas with a convenient and accessible online platform to access our services quickly and efficiently. With our redesigned website, we aim to further enhance the customer experience and continue exceeding expectations.”

In addition to its sleek aesthetic and user-friendly interface, the new website features informative content, helpful resources, and a user-friendly contact form, allowing customers to easily reach out to Ez Car Keyz Oxnard for inquiries, appointments, or emergency locksmith services. The launch of the redesigned website underscores Ez Car Keyz Oxnard’s commitment to innovation, customer satisfaction, and excellence in the automotive locksmith industry.

For more information about Ez Car Keyz Oxnard and its range of car locksmith services in Oxnard, CA, visit the newly redesigned website at https://ezkyz.com/

About Ez Car Keyz Oxnard:

Ez Car Keyz Oxnard is a leading provider of car locksmith services in Oxnard, CA. With years of experience and a commitment to excellence, Ez Car Keyz Oxnard offers a wide range of automotive locksmith solutions, including car key replacement, lockout assistance, ignition repair, and key fob programming. Committed to customer satisfaction and reliability, Ez Car Keyz Oxnard strives to deliver fast, efficient, and professional locksmith services to customers in Oxnard and the surrounding areas.

Media Contact
Company Name: Ez Car Keyz Oxnard
Contact Person: Niv Levy
Email: Send Email
Phone: 8058431590
Address:2137 N Ventura Rd, Oxnard
City: Ventura County
State: California 93036
Country: United States
Website: www.ezkyz.com/